Seeking Alpha

Teva (TEVA) enters into a JV with South Korea's Handok Pharmaceuticals to sell the Israel...

Teva (TEVA) enters into a JV with South Korea's Handok Pharmaceuticals to sell the Israel company's drugs in the country, where the market is worth $14B and where healthcare spending is expected to hit 9% of GDP within three years. The move fits in with Teva's new strategy, which includes expanding its global presence and carrying out more business development. (PR)
Comments (1)
  • Michael Bryant
    , contributor
    Comments (5582) | Send Message
     
    Out of the large cap drug markers, I think (TEVA), (NVO), (BIIB), and (GILD) are the best.
    17 Dec 2012, 08:24 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector